Month: September 2021

BEYOND / HELLO™ Colwyn Continues to Expand Access and Will Begin Serving Medical Marijuana Patients in the Philadelphia Region on Wednesday, September 8th at 10:00 a.m.Jushi Holdings Inc. Opens 22nd BEYOND / HELLO™ Retail Location Nationwide and 15th Store in PennsylvaniaJushi Holdings Inc. (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced the opening of its 22nd BEYOND / HELLO™ retail location nationwide, 15th medical marijuana dispensary in Pennsylvania and 7th storefront in the Greater Delaware Valley: BEYOND / HELLO™ Colwyn. Commenting on the opening Jim Cacioppo, Chief Executive Officer, Chairman and Founder of Jushi, said, “Our subsidiaries’ fifteenth location in Pennsylvania and seventh location in the Greater Delaware Valley Region demonstrates our commitment to expand...

Name change reflects investment in, and emphasis on, data-driven, patient-centric care relating to the company’s innovative PRP-PBMC treatment for chronic lung disorders. CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) — H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders, today announced the launch of its newly-named ‘Centers for Respiratory Health’. Effective immediately, the Company’s “Lung Health Institute” facilities will begin operating under the new name. The change is evolutionary and represents a commitment to data-driven, real-world evidence, along with the need to more accurately capture the broadening scope of the work the H-CYTE clinical development team and its medical professionals accomplish...

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13 – 15, 2021. Ms. Johnson’s presentation will be available on-demand for conference participants beginning at 7:00 a.m. Eastern Time on Wednesday, September 13th. Registration and other information about the event can be found at https://hcwevents.com/annualconference/. Following the conclusion of the conference, an archived webcast of Ms. Johnson’s presentation will be available until September 29, 2021 under “Presentations, Events & Webcasts” in the Investors section of the company’s...

Company Commences Second Study of Trypsin Activated Abuse Protected (TAAP) Opioid, PF614, on September 7, 2021 SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today announced that it has enrolled the first cohort of subjects in a clinical study PF614-102 entitled “A Phase 1b, Randomized, 2-Part Single-Center Study to Evaluate the Pharmacokinetics and Safety of Multiple-Ascending Oral Doses of PF614 and the Food Effect and Bioavailability/Bioequivalence of Single Oral Doses of PF614 Relative to OxyContin in Healthy Adult Subjects.” The study is being conducted by Matthew Johnston, MD, PRA Health Sciences,...

FLORHAM PARK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it has submitted two new drug applications (NDAs) to the U.S. Food and Drug Administration (FDA) for the use of vonoprazan in combination with amoxicillin and clarithromycin (vonoprazan triple therapy) and vonoprazan in combination with amoxicillin (vonoprazan dual therapy) as a treatment for Helicobacter pylori (H. pylori) infection in adults. With current standard of care therapies, H. pylori eradication rates have declined in the U.S. If approved, vonoprazan-based treatments offer two new therapeutic options that have demonstrated superior eradication rates as compared to...

Conference to Take Place Virtually, September 13-15, 2021 CHARLOTTESVILLE, Va., Sept. 08, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. The prerecorded presentation will be available starting at 7 a.m. ET on September 13, 2021 and will be accessible via the conference’s virtual platform by registered conference attendees. The presentation will be archived and available for viewing for 90 days, following the conference. Dr. Cobuzzi will provide...

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Sept. 08, 2021 (GLOBE NEWSWIRE) — Pure Gold Mining Inc. (TSXV:PGM LSE:PUR) (“Pure Gold Mining Inc.” or the “Company”) has today entered into an agreement with National Bank Financial Inc., as lead underwriter, on behalf of a syndicate of underwriters (collectively, the “Underwriters”) under which the Underwriters have agreed to purchase, on a bought deal basis, 19,048,000 units of the Company (“Units”) at a price of C$1.05 per Unit for gross proceeds of C$20,000,400 (the “Offering”). Each Unit is comprised of one common share (each a “Common Share”) and one-half Common Share purchase warrant (each such full warrant, a “Warrant”)....

Accelerating Heterogeneous Design and IntegrationHeterogeneous integration brings new kinds of design and manufacturing flexibility to semiconductor and systems companies by allowing chips of various technologies, functions and sizes to be integrated in one package. Applied Materials is combining its leadership in process technology and large-area substrates along with ecosystem collaborations to accelerate the industry’s heterogeneous design and integration roadmaps.New advanced software modeling and simulation for die-to-wafer hybrid bonding at Applied’s Advanced Packaging Development Center speeds customer time to market Enters into joint development agreement with EV Group for co-optimized wafer-to-wafer hybrid bonding solutions Enables larger, higher quality substrates for advanced packaging through the recent acquisition...

Sandoz enters into commercialization agreement for biosimilar bevacizumab with Bio-Thera Solutions, Ltd., for treatment of multiple types of cancers1,2 Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access, while contributing to sustainability of healthcare systemsBasel, September 8, 2021 — Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF), a key mediator of angiogenesis in cancer, and is used in combination with other treatments1,2. Bio-Thera Solutions, Ltd. will maintain responsibility for development and manufacturing, Sandoz will...

Marks the 37th Game Developed In-House for DraftKings Casino BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) — DraftKings Inc. (Nasdaq: DKNG) announced the addition of its new and exclusive game DraftKings Rocket to the DraftKings Casino product suite, which is currently available in New Jersey with Michigan and West Virginia to follow pending regulatory approval. Built entirely in-house, DraftKings Rocket is the latest addition to the more than 30 games that have been developed by internal team members and part of over 60 unique game builds in total. It also comes on the heels of the company’s latest iGaming expansions, which included the addition of both Spanish 21 and DKCraps earlier this year. “By developing DraftKings Rocket, our team continues to innovate our Casino offerings as we set out to create an all new, one-of-a-kind iGaming...